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Abstract
Objective To estimate the cost-effectiveness of adding a
selective phosphodiesterase-4 inhibitor, roflumilast, to a
long-acting bronchodilator therapy (LABA) for the treat-
ment of patients with severe-to-very severe chronic
obstructive pulmonary disease (COPD) associated with
chronic bronchitis with a history of frequent exacerbations
from the UK payer perspective.
Methods A Markov model was developed to predict the
lifetime cost and outcomes [exacerbations rates, life
expectancy, and quality-adjusted life years (QALY)] in
patients treated with roflumilast, which showed a reduction
in the exacerbation rates and lung function improvement in
a pooled analysis from two clinical trials, M2-124 and M2-
125. Sensitivity analyses were conducted to explore the
impact of uncertainties on the cost-effectiveness.
Results The addition of roflumilast to concomitant LABA
reduced the number of exacerbations from 15.6 to 12.7 [2.9
(95 % CI 0.88–4.92) exacerbations avoided] and increased
QALYs from 5.45 to 5.61 [0.16 (95 % CI 0.02–0.31) QALYs
gained], at an incremental cost of £3,197 (95 % CI £2,135–
£4,253). Cost in LABA alone and LABA ? roflumilast were
£16,161 and £19,358 respectively. The incremental cost-
effectiveness ratios in the base case were £19,505 (95 % CI
£364–£38,646) per quality-adjusted life-year gained and
18,219 (95 % CI £12,697–£49,135) per life-year gained.
Sensitivity analyses suggest that among the main determi-
nants of cost-effectiveness are the reduction of exacerbations
and the case fatality rate due to hospital-treated exacerba-
tions. Probabilistic sensitivity analysis suggests that the
probability of roflumilast being cost-effective is 82 % at
willingness-to-pay £30,000 per QALY.
Conclusions The addition of roflumilast to LABA in the
treatment of patients with severe-to-very severe COPD
reduces the rate of exacerbations and can be cost-effective
in the UK setting.
Keywords COPD  Cost-effectiveness analysis 
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Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
disease characterised by airflow limitation that is only par-
tially reversible and progresses over time. It is a major cause
of disability and death worldwide and has an estimated
prevalence in Europe of 7.6 %, with the prevalence of
physiologically defined COPD in adults C40 years of
approximately 9–10 % [1]. COPD patients present with
symptoms of cough, sputum production, or dyspnoea, and a
history of exposure to risk factors, of which smoking is the
most important. Symptoms, including activity limitation,
and COPD exacerbations place a heavy burden on patients
and impair their quality of life [2–4]. Spirometric criteria
used to confirm the diagnosis of COPD are a post-broncho-
dilator FEV1/FVC (Tiffeneau index) of\0.7. COPD is judged
as severe when the FEV1 is between 50 and 30 % and very
severe when it is below 30 % of the predicted value [2, 5].
Exacerbations of COPD are characterised by a change in
the patient’s baseline dyspnoea, cough, and/or sputum that
is beyond normal day-to-day variations, are generally acute
in onset, and may prompt a change in regular medication
[2]. Exacerbations vary in severity and are responsible for
much of the cost of managing COPD. In most clinical and
health economics studies of COPD, the severity of an
exacerbation is defined by the level of health resources
required in their management. Moderate exacerbations are
those requiring oral or parenteral corticosteroids [6–8],
while severe exacerbations are those leading to hospital
admission and/or death.
The frequency of exacerbations are higher in COPD
patients with chronic cough [9], and the risk of all-cause
mortality is higher in COPD patients with a chronic
bronchitis [10, 11]. The impact of exacerbations requiring
hospital admission upon health status is particularly severe,
affecting mobility and self-care [12, 13].
The goals of management of COPD are to limit disease
progression, through reduction of risk factors such as
smoking, to reduce the frequency of exacerbations, and to
improve quality of life. Pharmacological management
involves a stepwise increase in treatment according to a
combined assessment of ‘‘risk’’ based on symptoms, severity
of lung function impairment, and risk of exacerbations [2],
beginning with the as-needed use of short-acting bronchod-
ilators (SABA) followed by the addition of one or more long-
acting bronchodilators (LABA) or a long-acting antimu-
scarinic (LAMA) with or without an inhaled corticosteroid
(ICS) [2]. With increasing severity of COPD the use of
combinations of these treatments is recommended [5]. None
of these treatments have been shown conclusively to modify
the long-term decline in lung function that characterises
COPD.
In 2010, roflumilast, a selective phosphodiesterase-4
inhibitor with antiinflammatory properties, was approved by
European Medicines Agency (EMA) for use as once-daily
oral maintenance treatment for adult patients with severe and
very severe COPD associated with chronic bronchitis and a
history of frequent exacerbations as an add-on to bron-
chodilators [14]. The effect of roflumilast on exacerbation
rates in patients with COPD was investigated in two placebo-
controlled double-blind multicentre trials (M2-124 and M2-
125) with similar populations of patients with COPD [6].
Both studies compared roflumilast add-on therapy with
placebo in patients with a mean age of 64.7 years with a
clinical diagnosis of severe-to-very severe COPD and a
chronic productive cough and were designed so that
approximately 50 % of patients received concomitant
treatment with LABA, a pre-specified subgroup of patients
[15]. This enabled the comparison of roflumilast plus LABA
versus LABA alone. Analysis of the combined patient pop-
ulation in both studies [6] showed a statistically significant
reduction of exacerbation rates in patients treated with rof-
lumilast added to concomitant LABA compared to patients
treated with LABA alone [relative reduction of exacerbation
rates of 0.793 (95 % CI 0.690–0.911)] [15] and a statistically
significant increase in post-bronchodilator FEV1 of 46 ml
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(95 % CI 28–64). A further analysis of efficacy confirmed
that the difference in exacerbation rates between treatments
was independent of concomitant LABA [6] and that the time
to first and second exacerbations was lengthened with rof-
lumilast treatment [15].
The objective of the cost-effectiveness analysis reported
in this article is to assess the cost-effectiveness of con-
comitant LABA ? roflumilast versus LABA alone, as
consistent with the label for roflumilast. The analysis is
based on the pooled evidence from trials M2-124 and M2-
125 [6, 15, 16] and the current indication for roflumilast.
Methods
Model structure
A state-transition Markov model was constructed to esti-
mate the life-time cost and health outcomes and the cost-
effectiveness of roflumilast added to concomitant LABA
treatment in a cohort based on the patient population in the
studies M2-124 and M2-125. Patients’ characteristics in the
model cohort, such as mean age, proportion of males, rates
of exacerbations in the LABA alone group, the proportion
of exacerbations treated in hospital, and the relative
reduction of exacerbation rates (RRR) and FEV1
improvement in patients treated with roflumilast added to
concomitant LABA, were based on the LABA subgroup in
studies M2-124 and M2-125 [6, 15] and are presented in
Table 1. The model was implemented in the TreeAge Pro
2009 Suite (TreeAge Software Inc.) with a Microsoft
Office Excel 2003 (Microsoft Corporation) front end.
The model included three states: severe COPD, very
severe COPD, and dead. COPD states in the model are
based on the severity of the disease as defined by the
GOLD criteria [2], i.e. using post-bronchodilator FEV1%
predicted value relative to the normal population. The
model cycle length is 1 month, and the time horizon of the
model is 30 years, which is considered a lifetime horizon,
given the mean age of patients at start of 64.7 years.
Transitions in the model simulate the progression of
COPD, exacerbations, and death. Exacerbations are mod-
elled as events that can occur in the severe and very severe
COPD states. Patients who experience exacerbations
within a model cycle can remain in their respective COPD
state, transition to very severe COPD (patients with severe
COPD), die because of background mortality, or die as a
result of hospital-treated exacerbations. Patients without
exacerbations can die because of background mortality,
progress to very severe COPD (for patients in the severe
COPD state), or remain in their respective COPD state. The
disease states and transitions are shown in Fig. 1.
Table 1 Base case and key model inputs
Parameter Value Distribution
in PSA
Age of the cohort at the start of the
model, yearsa
64 N/A
Proportion of patients who start the
model in severe COPD
1.0 N/A
Mean FEV1% in severe COPD at
the start of the model, %
40 N/A
Proportion of males in the cohorta 0.75 N/A
Mean height of males in the model,a
cm
171.3 N/A
Mean height of females in the
model,a cm
161.7 N/A
Rate of exacerbations in the severe
COPD state in the LABA group,b
per patient per year
1.458 (95 % CI
1.292–1.646)
Gamma
Rate of exacerbation in the very
severe COPD state in the LABA
group,b per patient per year
1.776 (95 % CI
1.447–2.179)
Gamma
Proportion of exacerbations that
require hospitalisation in the
severe COPD statec
0.155 (95 % CI
0.133–0.178)
Beta
Proportion of exacerbations that
require hospitalisation in the very
severe COPD state
0.244 (95 % CI
0.208–0.280)
Beta
Relative ratio of exacerbation rates
in the LABA ? roflumilast arm
versus LABA aloned
0.794 (95 % CI
0.7–0.91)
Lognormal
Post-bronchodilator FEV1
improvement due to roflumilast,e
L
0.046 (95 % CI
0.028–0.064)
Gamma
Duration of function benefit in the
LABA ? roflumilast arm, years
1 N/A
FEV1 decline per year with COPD,
f
L
0.052 (95 % CI
0.031–0.062)
Gamma
SMRB—for background mortality
(excluding hospital death) in the
severe COPD stateg
2.5 Uniform
SMRB—for background mortality
(excluding hospital death) in the
very severe COPD stateg
3.85 Uniform
Probability of death due to hospital-
treated exacerbations (case fatality
rate), at age 73h
0.077
(SE = 0.044)
Beta
Utility for the severe COPD stateb 0.751 (95 % CI
0.738–0.765)
Beta
Utility for the very severe COPD
stateb
0.657 (95 % CI
0.635–0.678)
Beta
Annual utility reduction associated
with a community-treated
exacerbationi
0.01 (95 % CI
0.0–0.024)
Beta
Annual utility reduction associated
with a hospital-treated
exacerbationi
0.042 (95 % CI
0.0–0.06)
Beta
Monthly cost of roflumilast,j £ 38.23 N/A
Monthly cost of LABA, £k 29.67 N/A
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COPD progression
The progression from the severe to very severe COPD state
depends on the baseline average FEV1 value (L) and the
estimated lung volume decline in the COPD cohort. FEV1
naturally declines with age in the general population [17], but
more rapidly in patients with COPD (52 ml per year [18]).
Predictive equations for lung function for males and females
in the general population were taken from a study of refer-
ence spirometric values in non-smoking men and women
[17]: FEV1 (men), L = (0.0414 9 height) - (0.0244 9
age) - 2.190; FEV1 (women), and L = (0.0342 9
height) - (0.0255 9 age) - 1.578 (height in cm). Monthly
probabilities of progression of patients from the severe
COPD state to the very severe COPD state were derived from
the estimated time required for FEV1 in the severe COPD
state to reach the 30 % post-bronchodilator FEV1% thresh-
old, corresponding to the definition of very severe COPD.
The cycle probability of transition from the severe COPD
state to the very severe COPD state was estimated as the
reciprocal of the average estimated time (T) in the severe
COPD state for males and females separately. The average
estimated time (T) in the severe COPD state was derived
from the intersection of the line that represents lung function
in patients with COPD with the line that represents 30 % of
the lung function in the normal population (Fig. 2).
Exacerbations
Exacerbations in the model are either moderate (i.e. com-
munity-treated) or severe (i.e. requiring hospital admission),
each associated with costs and health outcomes. Moderate
exacerbations in the studies M2-124 and M2-125 were
defined as those requiring systemic treatment with oral ste-
roids [6, 15]. The annual rates of exacerbations from a pooled
analysis of a pre-specified subgroup of patients treated with
concomitant LABA in studies M2-124 and M2-125 [16]
were used to estimate the baseline exacerbation rates in the
LABA alone arm. A pooled analysis was possible because of
the identical design of the studies M2-124 and M2-125 [6].
Exacerbation rates in the treatment arm (LABA ? roflumi-
last) are expressed via the baseline rate of exacerbations in
the LABA alone arm and a relative reduction of exacerbation
rates (RRR) associated with treatment.
The baseline annual exacerbation rates were estimated
separately for patients in the severe and in very severe
COPD states and equalled 1.458 (95 % CI 1.292–1.646)
and 1.776 (95 % CI 1.447–2.179) respectively. Fixed
proportions of all exacerbations in the severe and the very
severe COPD states are hospital-treated exacerbations,
based on estimates from the pooled analysis of trial data
and equalled 0.155 (95 % CI 0.133–0.178) in the severe
COPD state and 0.244 (95 % CI 0.208–0.280) in the very
severe COPD state [19].
Mortality
Mortality in the modelled COPD cohort occurs as both a
result of case fatality during a hospital-treated exacerbation
and as age- and sex-specific background mortality that
excludes hospital mortality. In the model, the background
mortality and the hospital mortality combined represent the
all-cause mortality in populations with severe and very
severe COPD.
Hospital mortality
The risk of death due to a hospital-treated exacerbation
(case fatality rate, CFR) was obtained from the 2008 UK
National COPD Audit Report [20] where CFR was repor-
ted at 7.7 % for a sample of 9,716 admissions for COPD
exacerbations (with subsequently estimated SE of 4.4 %).
Table 1 continued
Parameter Value Distribution
in PSA
Average cost of severe (hospital-
treated) exacerbation, £l
1,381 (95 % CI
1065–1698)
Gamma
Average cost of community-treated
exacerbation, £m
66 (95 % CI
41–90)
Gamma
Cost of maintenance of patients in
severe COPD, per month, £n
48 (95 % CI
34–61)
Gamma
Cost of maintenance of patients in
very severe COPD, per month, £n
149 (95 % CI
122–176)
Gamma
a Based on [6]
b Derived from pooled analysis of clinical studies M2-124 and M2-
125 [16]; reported in [38]
c Reported in [19]
d Reported in [15] and adjusted to eliminate the potential double-
counting due to indirect reduction of exacerbation rates resulting from
the lung function benefit
e Reported in [38]
f Lung function decline in [18]
g Based on [22], estimated for the UK population in NICE COPD
Guideline CG101[5]
h Based on [20] and adjusted to age of patients in modelled cohort
i In the model, the annual reduction of utilities due to an event of
exacerbation reported in [23] was accounted for a 1-month model
cycle
j Roflumilast: estimated manufactured price at the recommended
daily dose of 500 lg
k LABA: Serevent, at daily dose of 50 lg [24]
l Non-elective HRG, including short-stay admissions [25]
m Includes cost of a GP visit, cost of an accident and emergency
admission, and medications
n Based on resource use reported in [12] and respective UK unit costs
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The average age of patients in the UK COPD Audit Report
was 73 years. The average age of patients in the model at
the start of the simulation was 64 years. To avoid overes-
timation of hospital mortality at the start of cohort simu-
lation we assumed that hospital mortality risk would be
lower in patients younger than 73 years and increase in
patients older than 73 years, and we used the ratio of age-
specific risk of death in the general population to the risk of
death at the age of 73 to adjust the CFR value of 7.7 %.
With such an adjustment, at the age of the cohort of
64 years, the resultant hospital CFR was 3.2 % (where
100 % of the cohort patients were alive), further reaching
the value of 7.7 % at the cohort age of 73 years (when
52 % of cohort patients were alive) and approaching the
level of 28 % at the age of 85 years (with only 2.4 % of the
cohort patients alive), as shown in Table 2. In a scenario
analysis, an alternative estimate of the age adjustment of
the risk of hospital mortality reported in a meta-analysis
study [21] was tested.
Background mortality and SMR
In the model, the risk of background mortality in the severe
and very severe COPD states is expressed via the age- and
sex-specific mortality in the general population multiplied
by standardised mortality ratios for background mortality
M 
Severe  COPD 
Very Severe COPD 
Dead 
Stay alive 
Die 
Exacerbation 
No exacerbation 
Hospital 
Community 
Discharge 
Hospital death 
No COPD progression 
COPD progression 
No COPD progression 
COPD progression 
COPD Progression 
No COPD progression 
Stay alive 
Die 
Exacerbation 
No exacerbation  
Hospital 
Community 
Discharge 
Hospital death 
Stay in  
Severe COPD 
Progress to  
Very Severe COPD 
Stay in  
Severe COPD 
Stay in  
Severe COPD 
Progress to  
Very Severe COPD 
Stay in  
Very Severe COPD 
Stay in  
Very Severe COPD 
Stay in  Very Severe COPD 
Markov 
Cohort (M,F) 
Progress to  
Very Severe COPD 
Severe 
COPD 
Very 
severe 
COPD 
Dead 
Health states 
Disease progression Exacerbations Fig. 1 COPD Model structure
states and transitions. Transition
from severe COPD to very
severe COPD is irreversible. In
the tree diagram, the model
cohort is represented by males
and females separately because
of the differences in rates of the
disease progression and
background death for males and
females. Encircled M Markov
node, circle chance node, left
pointing triangle terminal node
(transition to a different state or
exacerbation within the current
state)
Table 2 Hospital case fatality rate (CFR) adjusted to age of cohort
Age (M/F), years 64 70 73 75 80 85
Adjustmenta 0.46 0.73 1.00 1.24 2.15 3.68
Hospital CFR 0.035 0.057 0.077b 0.095 0.166 0.283
Proportion of cohort
alive (%)c
100 69 52 39 15 2.4
a Adjustment using the ratio of the age-specific risk of death in the
UK general population to the risk of death in the UK general popu-
lation at the age of 73, the average age in the UK COPD Audit Report
[20]
b Source: 2008 UK COPD Audit Report [20]
c Estimated from model simulation
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that excludes hospital deaths (SMRB). The relative mortality
risk ratio by COPD GOLD stage versus non-COPD popu-
lation was based on a Swedish study [22] that provided
estimates of the relative COPD mortality risk of the FEV1
group compared with the general population mortality. The
all-cause mortality SMR in severe COPD was estimated at
3.1 (95 % CI 2.6–4.1) and in very severe COPD 5.0 (95 % CI
3.5–11.8) as the weighted average for smokers, former
smokers, and never smokers stratified by GOLD COPD
severity stage and gender compared to the general population
without symptoms of chronic bronchitis and with normal
pulmonary function. The values of SMRB (which exclude
hospital deaths) were subsequently estimated by separating
the hospital case fatality rate multiplied by the risk of hos-
pital-treated exacerbations from the risk of all-cause mor-
tality in severe and very severe COPD separately and were
estimated at 2.5 and 3.85 for the severe and very severe
COPD states respectively (shown in Table 3). The impact of
the estimated SMRB on the incremental cost-effectiveness
was explored in a sensitivity analysis and was found to have
little impact on the incremental cost-effectiveness (Table 6).
Health-related utilities
Two types of health-related utilities are employed in the
model. The severe COPD and very severe COPD states are
associated with the utility values of 0.751 (95 % CI
0.738–0.765) and 0.657 (95 % CI 0.635–0.678) respectively
[16]. Hospital-treated exacerbations and community-treated
exacerbations cause loss of utility that is translated in the
model into loss of QALY per an event of exacerbation. The
QALY loss due to an exacerbation was estimated based on
the annual utility reduction of 0.01 (SE = 0.007) and 0.042
(SE = 0.009) associated with a community-treated exacer-
bation and a hospital-treated exacerbation respectively,
reported in [23]. In the model, the loss of QALY was applied
to the model cycle within which an exacerbation occurred;
therefore the values of absolute reduction of health-related
utilities within 1 month in the model equalled 0.12 (repre-
senting a loss of QALY per a moderate exacerbation of 0.01)
and 0.504 (representing a loss of QALY per severe exacer-
bation of 0.042) due to a community-treated exacerbation
and due to a hospital-treated exacerbation respectively.
Resource use and costs
The cost-economic analysis was conducted from the per-
spective of the UK National Health Service (NHS). Costs
and outcomes were discounted at 3.5 % per annum. The
following direct health care costs are considered in the
model: (1) monthly costs of maintenance of a patient in the
severe and very severe COPD states; (2) monthly costs per
patient of roflumilast ? LABA and LABA, and (3) event
costs of community-treated and hospital-treated exacerba-
tions. Maintenance costs included outpatient visits, oxygen
therapy, spirometry tests, and influenza vaccinations [12]
and amounted to £48 (95 % CI £34–£61) and £149 (95 % CI
£122–£176) per month for patients with severe and very
severe COPD respectively (Table 4). The monthly costs of
roflumilast was £38.23 (estimated manufacturer price at the
recommended daily dose of 500 lg), and the monthly cost of
LABA was £29.67 [Serevent (Salmeterol)] at a daily dose
of 50 lg [24]. The cost of a community-treated exacerbation
was estimated at £65 (95 % CI £41–£89). The cost of a
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Time from the start of cohort simulation, years
treatment effect = 46 mL, lasting for 1 year 
time to very severe COPD
Increased time to very severe COPD
Fig. 2 Lung function decline and lung volume improvement (shaded
area shows the duration of treatment effect for 1 year in the base
case). The diagram shows the decline of lung volume (FEV1) in
patients with severe COPD at the rate of 52 ml per year and the 30 %
line of lung volume in the general healthy population representing the
GOLD definition of very severe COPD. FEV1 (males),
L = (0.0414 9 height) - (0.0244 9 age) - 2.190; FEV1 (females),
L = (0.0342 9 height) - (0.0255 9 age) - 1.578 [17. The pro-
jected time to progression from the severe to very severe COPD
state is estimated at the intercept of the two lines. A lung function
benefit is modelled as an increase of lung volume by 46 ml for 1 year
and a return to the lung volume of the LABA alone group; the annual
rate of decline of lung volume remains the same in the roflumi-
last ? LABA and LABA alone groups
Table 3 Standardised mortality ratios for background mortality by
COPD severity stage
Severe COPD Very severe
COPD
Estimated SMRB for
background deatha
2.50 3.85
All-cause SMRb 3.1 (95 %
CI 2.6–4.1)
5.0 (95 %
CI 3.5–11.8)
a Mortality risk by GOLD stage versus non-COPD population
(applied to age-specific mortality rates for the UK general popula-
tion). Derived based on all-cause SMR in [22] and [5]; the mortality
risk associated with hospital-treated exacerbations was deducted from
all-cause SMR
b Source: A Swedish study [22] where SMRs were estimated as
weighted average for smokers, former smokers, and never smokers
stratified by GOLD COPD severity stage and gender compared to the
general population without symptoms of chronic bronchitis and with
normal pulmonary function
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hospital-treated exacerbation was based on non-elective
Healthcare Resource Groups (HRGs) weighted by volume
[25], related to COPD, that also included HRGs for short
hospital stays and was estimated at £1,381 (95 % CI £1,065–
£1,698) (Table 4).
Reduction of exacerbations
A relative rate reduction (RRR) of exacerbations of 0.793
(95 % CI 0.690–0.911) was derived for severe COPD and
very severe COPD combined, using pooled data from trials
M2-124 and M2-125 [15] for the pre-specified subgroup of
patients treated with concomitant LABA. In the model, this
RRR was adjusted to eliminate the potential double-
counting due to indirect reduction of exacerbation rates
resulting from the lung function improvement (i.e. slowing
down the progression of disease to very severe COPD).
The adjusted relative reduction of the exacerbation rate
ratio applied in the model was 0.794 (95 % CI 0.70–0.91).
The reduction of exacerbations due to treatment reduces
the effect of exacerbations on the health-related utility and
subsequently leads to a reduction in mortality due to hos-
pital-treated exacerbations. In the model it was assumed
that the reduction of exacerbations lasts for the lifetime
horizon. In one-way sensitivity analysis, shorter durations
of the reduction of exacerbations were tested.
Lung function improvement
Roflumilast add-on treatment has been shown to improve
lung function [6]. This treatment effect was implemented
in the model as an increase in FEV1 (an improvement in
post-bronchodilator FEV1 of 46 ml (95 % CI 28–64) in
patients treated with concomitant LABA ? roflumilast.
The lung volume increase did not have an impact on the
annual decline of lung volume, which remained equal to
52 ml in patients in the treatment and comparator arms. In
the base case analysis, the lung function benefit of roflu-
milast was limited to 1 year, as observed in studies M2-124
and M2-125. After 1 year, it was assumed that the lung
volumes in patients in the roflumilast and comparator arms
were equal. Improvement of lung function results in an
increased time that patients stay in the severe COPD state,
delaying the transition to the very severe COPD state.
Figure 2 shows the impact of the improvement of lung
function on the average estimated time in the severe COPD
state. The impact of a longer duration of lung function
benefit was explored in a sensitivity analysis.
Adverse events
The majority of adverse events in patients treated with
roflumilast in studies M2-124 and M2-125 were mild-to-
moderate and transient and occurred within the first month
from the beginning of treatment. In the model base case
analysis, adverse events were therefore not taken into
consideration. In a sensitivity analysis, an impact of
adverse events was assessed by assuming within the first
cycle health impact and costs of treatment of adverse
events per patient at 50 % of the average cost and 50 % of
the health impact of a community-treated exacerbation.
Probabilistic sensitivity analysis
In order to explore the combined impact of all uncertainties
in the model inputs on the cost-effectiveness, a probabi-
listic sensitivity analysis (PSA) was conducted. The list of
the input parameters included in the PSA and the corre-
sponding distributions with their respective 95 % CIs are
shown in Table 1. The gamma distribution was used for the
costs, the annual lung volume decline, the lung volume
improvement, and the background rates of exacerbations in
the LABA only arm. The beta distribution was used for the
proportion of hospital-treated exacerbations, the hospital
case fatality rate, and the health-related utilities associated
with COPD and the disutilities of exacerbations. Log-nor-
mal distribution was applied to the treatment effect
(reduction of exacerbation rates). For standardised mor-
tality ratios for background death uniform distributions
were used, cantered around the mean values. The number
of iterations in the PSA was 2,000; the PSA results are
presented in Fig. 3 as an incremental scatter plot and the
cost-effectiveness acceptability curve (CEAC).
A summary of health benefits of roflumilast
The benefits of adding roflumilast to concomitant bron-
chodilator therapy (LABA) predicted by the model result
from the reduction of exacerbation rates and from the
improvement in lung function. The reduction of exacer-
bation rates reduces the QALY loss from exacerbation
events and reduces mortality because of the reduction of
hospital-treated exacerbations. The improvement in lung
function delays the progression of patients from the severe
COPD to the very severe COPD state, which is associated
with lower health-related utility, higher maintenance costs,
higher frequency of exacerbations, and higher background
mortality (SMRB).
Results
Base case analysis and PSA
For the LABA alone arm, the model (Table 5) predicts the
discounted life expectancy of 8.0 years (95 % CI
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6.84–9.15), the mean quality-adjusted life expectancy
(QALY) of 5.45 (95 % CI 3.96–6.94), and the number of
exacerbations of 15.64 (95 % CI 9.56–21.72). The cost per
patient amounts to £16,161 (95 % CI £10,039–£22,013).
For the LABA ? roflumilast arm, the mean discounted
life expectancy yields 8.17 years (95 % CI 5.84–10.50),
quality-adjusted life expectancy 5.61 (95 % CI 4.08–7.15)
QALYs, and 12.7 exacerbation (95 % CI 7.56–17.92).
Treatment with add-on roflumilast resulted in incremental
life expectancy 0.18 years (95 % CI -0.03 to 0.38),
incremental QALYs 0.16 (95 % CI 0.02–0.31), and 2.9
fewer exacerbations (95 % CI 0.88–4.92). The incremental
cost-effectiveness ratio (ICER) associated with adding
roflumilast to LABA amounts to £19,505 (95 % CI £364–
£38,646) per QALY gained and to £18,219 per life-year
gained (95 % CI -£12,697 to £49,135).
Probabilistic sensitivity analysis (PSA)
The uncertainty in the cost-effectiveness was explored in a
probabilistic sensitivity analysis using Monte-Carlo simu-
lation [26]. The cost-effectiveness scatter plot and cost-
effectiveness acceptability curve (CEAC) are presented in
Fig. 3; the probability of roflumilast as an add-on to LABA
versus LABA alone being cost-effective is 82 % at will-
ingness-to-pay £30,000 per QALY.
One-way sensitivity analysis (OWSA)
A range of one-way sensitivity analyses (OWSA) were
performed to explore the impact of uncertainty in model
parameters on the incremental cost-effectiveness. The lower
and upper estimates for variables in the OWSA were based,
where possible, on the boundaries of the respective 95 %
confidence intervals, or on the assumptions, and are pre-
sented in Table 6.
Relative reduction of exacerbation rates
The predicted cost-effectiveness is most sensitive to the
relative reduction of exacerbations rates (RRR) and varied
from £12,829 per QALY gained to £53,435 per QALY
gained when RRR varied from the lower to upper bounds of
its 95 % CI respectively. In the model, it is assumed that the
treatment effect of reduction of exacerbation rates applies for
the entire duration of simulation (a lifetime horizon) as there
is no evidence from the roflumilast studies to suggest a
reduction of the treatment effect of roflumilast with time.
However, a scenario analysis was performed to explore the
cost-effectiveness with the assumption of a limited duration
of the treatment effect. In that scenario analysis, both the
treatment effect and the cost of roflumilast were removed
after a number of years. In this scenario analysis the incre-
mental cost-effectiveness ratio (ICER) remained stable
within a wide range of assumptions on the duration of
treatment effect (years): £10,966 (1 year), £16,515
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Fig. 3 Probabilistic sensitivity analysis: incremental cost-effective-
ness scatter plot (a) and cost-effectiveness acceptability curve (b)
Table 5 Cost-effectiveness analysis, base case
LABA roflumilast ? LABA Incremental
Costs, £ 16,161 (95 % CI 10,039–22,013) 19,358 (95 % CI 12,711–26,050) 3,197 (95 % CI 2135–4259)
QALYs 5.451 (95 % CI 3.96–6.94) 5.615 (95 % CI 4.08–7.15) 0.164 (95 % CI 0.02–0.31)
Life years 8.0 (95 % CI 6.84–9.15) 8.17 (95 % CI 5.84–10.50) 0.175 (95 % CI -0.03 to 0.38)
Number of exacerbations 15.64 (95 % CI 9.56–21.72) 12.74 (95 % CI 7.56–17.92) -2.9 (95 % CI 0.88–4.92)
Cost per QALY gained, £ 19,505 (95 % CI 364–38,646)
Cost per LY gained, £ 18,219 (95 % CI -12,697 to 49,135)
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Table 6 Uncertainty in model parameters and one-way sensitivity analysis
Sensitivity and scenario analyses Parameter values ICER, £/QALY
Base case values
(95 % CI)
Low
estimate
High estimate Source At
parameter
low
estimate
At
parameter
high
estimate
Base case incremental cost-effectiveness ratio, £ per QALY gained 19,505
Discount rate, costs (% per annum) 3.5 % 0 % 6 % Assumption 24,377 17,001
Discount rate, effects (% per
annum)
3.5 % 0 % 6 % Assumption 14,111 23,919
Discount rate costs and effect (%
per annum)
3.5 % 0 % 6 % Assumption 17,636 20,848
Cohort characteristics—proportion
of males (males:females)
0.75:0.25 0:1.0 1.0:0 Assumption 17,153 20,587
Proportion of patients in cohort
who start in severe COPD
0 (all start in
very severe
COPD)
1.0 (all start
in severe
COPD)
1.0 Assumption 17,792 19,505
Mean cohort age at start of model
(years)
64 60 70 Assumption 20,824 17,752
Relative ratio of exacerbation rates 0.794 0.70 0.93 95 % CI 12,829 53,435
Rate of exacerbations in the severe
COPD state in the LABA group
(per patient per year)
1.458 1.292 1.646 95 % CI 20,475 18,501
Rate of exacerbations in the very
severe COPD state in the LABA
group (per patient per year)
1.776 1.447 2.179 95 % CI 21,876 17,217
Proportion of exacerbations that
require hospitalisation in the
severe COPD state
0.155 0.133 0.178 95 % CI 20,439 18,608
Proportion of exacerbations that
require hospitalisation in the very
severe COPD state
0.244 0.208 0.280 95 % CI 21,005 18,207
Utility in severe COPD 0.751 0.738 0.765 95 % CI 19,671 19,329
Utility in very severe COPD 0.657 0.635 0.678 95 % CI 19,687 19,334
Utility decrement for a community-
treated exacerbation (absolute,
applied for 1 month)
0.12 0.00 0.29 95 % CI 22,117 16,707
Utility decrement for a hospital-
treated exacerbation
0.504 0.21 0.72 95 % CI 20,908 18,569
Hospital mortality—CFR at age 73 0.077 0.0 0.14 Assumption 47,963 15,031
SMRB (excluding hospital
mortality) in severe COPD
2.5 1 (no
increase of
mortality)
3.85 (same as in very severe
COPD)
Assumption 18,183 20,534
SMR (excluding hospital
mortality) in very severe COPD
3.85 2.5 (same in
severe
COPD)
5.2 Assumption 18,495 20,419
SMRB (excluding hospital
mortality) in the severe and very
severe COPD states
2.50 and 3.85
respectively
Base
case:50 %
for both
SMRB
Base case ? 50 % for both SMRB Assumption 16,363 21,777
Annual lung volume decline in
COPD population, litres
0.052
(95 % CI
0.031–0.062)
0.031 0.062 95 % CI 20,844 19,052
Lung function benefit for
roflumilast, litres
0.046
(95 % CI
0.028–0.064)
0.028 0.064 95 % CI 20,312 18,818
Duration of lung function benefit,
years
1 No benefit 5 Assumption 21,901 14,889
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(2 years), £20,369 (5 years), £20,298 (10 years), and
£19,543 (20 years) per QALY gained.
Hospital CFR
In the absence of hospital mortality, the ICER was esti-
mated at £47,963 per QALY. At higher CFR (14 % at age
73), the ICER was £15,031 per QALY gained. This upper
limit of 95 % CI of hospital CFR at age 73 in the model is
close to the CFR value of 15.6 % (95 % CI 10.9–20.3)
reported in a meta-analysis study [21].
This age adjustment of hospital CFR in the model results
in a lower risk of hospital CFR at the beginning of simu-
lation at age 64 (approximately 3.3 %) compared to the age
adjustment to CFR reported in [21] (4 % increase per
1 year of age). In a sensitivity analysis, we applied a CFR
of 0.077 at age 74 and adjusted it by increasing the risk of
death by 4 % per year of age in patients older than 73 and
by reducing the risk of death by 4 % per year in patients
younger than 73. This resulted in an ICER of £17,720 per
QALY gained. An assumption of constant CFR of 0.077
regardless of cohort age results in an ICER of £16,205 per
QALY gained. The assumption taken in the model repre-
sents therefore a more conservative approach to estimating
the risk of hospital mortality.
Duration of lung function benefits
At 1-year duration of lung function benefits, the mag-
nitude of improvement of lung function has a moderate
impact on the cost-effectiveness: the ICER varied from
£20,312 to £18,818 per QALY gained at FEV1 benefits
ranging from 28 to 64 ml (representing the lower and
upper limits of 95 % CI). When no lung function benefit
is assumed, the ICER amounts to £21,901 per QALY
gained. It such a case, the effect of treatment is deter-
mined by the reduction of exacerbations only. An
assumption of lung function benefits lasting for 2 and
5 years results in ICERs of £17,712 and £14,889 per
QALY gained respectively (Table 6).
Rate of exacerbations and patients with frequent
exacerbations
The cost-effectiveness is more sensitive to the background
rate of exacerbations in the very severe COPD state in
patients treated with LABA alone [ICER = £17,217 per
QALY and £21,876 per QALY gained at the annual
exacerbation rates of 2.18 and 1.45 (95 % CI)] than to the
rate of exacerbation in the severe COPD state
[ICER = £18,501 per QALY and £20,475 at annual
exacerbation rates of 1.65 and 1.29 (95 % CI)].
The cost-effectiveness was explored at the annual rate of
exacerbations of C 2 per patient in the severe COPD state
to represent patients with frequent exacerbations, as
defined in the 2011 Global Strategy for the Diagnosis,
Management and Prevention of COPD [2]. With the
assumed higher annual rates of exacerbations of 2.0, 2.25,
and 2.5 in the severe COPD state and the proportionately
increased rates of exacerbations in the very severe COPD
state, the estimated ICERs yield £14,120, £12,492, and
£11,192 per QALY respectively.
Table 6 continued
Sensitivity and scenario analyses Parameter values ICER, £/QALY
Base case
values(95 % CI)
Low
estimate
High estimate Source At
parameter
low
estimate
At
parameter
high
estimate
Cost of severe COPD disease
management, £ per month
48 34 61 95 % CI 19,398 19,608
Cost of very severe COPD disease
management, £ per month
149 122 176 95 % CI 20,083 20,504
Cost of a community-treated
exacerbation, £
65
(95 % CI 41–89)
41 89 95 % CI 19,785 19,218
Cost of a hospital-treated
exacerbation, £
1381
(95 %
CI 1065–1698)
1065 1698 95 % CI 20,445 18,563
Adverse events No AE 50 % cost of moderate
exacerbation and 50 % of loss of
QALY due to moderate
exacerbation
Assumption 19,505
(base
case)
20,322
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Background mortality
The assumption regarding the values of SMRB for background
mortality (excluding hospital mortality) did not have consid-
erable impact on the cost-effectiveness: at SMRB in severe
COPD varying from 1.0 to 3.85, the ICER changes from
£18,183 to £20,534 per QALY gained respectively. Similarly,
varying SMRB in the very severe COPD state from 2.5 to 5.2
changes the ICER from £18,495 to £20,419 per QALY gained.
Time horizon
The time horizon in the base case was lifetime (30 years in
the model). At shorter time horizons the incremental cost-
effectiveness was £59,690 per QALY (1 year), £49,824 per
QALY (2 years), £44,336 QALY (3 years), £36,909
(5 years), and £26,522 (10 years) per QALY gained.
Discussion
The economic analysis conducted in this study is built upon
the commonly accepted approaches taken in the previously
published pharmacoeconomic models in COPD [12, 13, 27–
30], with the efficacy of treatment derived from pooled analysis
of two clinical trials. Generally, earlier cost-effectiveness
studies have modelled COPD with disease states and transitions
determined by lung function (FEV1) assuming, with some
variations, that the effect of treatment leads to the delay of time
to transition to more severe disease states and to a reduction of
the rates of exacerbations. The existing variety of methods in
the application of lung function benefits, mortality, and utilities
suggests that there is no consensus on the best practice in the
application of these factors in COPD modelling. The accuracy
of the model presented in this study and other models is also
limited by the evidence from clinical trials that typically have
limited duration compared to the natural history of disease and
therefore by the need to use external data, such as reduction of
health-related utilities due to exacerbations and estimated of
background mortality and hospital mortality.
In this study, two key methods were employed to adjust
the estimates of hospital mortality and background mortality.
First, the model uses the hospital case fatality rate due to
severe exacerbations to assess potential survival benefits
associated with avoidance of hospital-treated exacerbations,
with the hospital case fatality rate sourced from a UK 2008
COPD Audit Report [20]. Subsequently, the value of CFR of
7.7 % reported in the UK COPD Audit Report was adjusted
to reflect the difference in age within the modelled cohort
(64 years at start) and in patients in the UK COPD Audit
Report (73 years). This conservative assumption was made
in order not to overestimate deaths from severe exacerba-
tions in younger cohort in the initial period of Markov cohort
simulation.
Second, the all-cause SMR generated by the model that
comprises SMRB for the background mortality and the
hospital CFR was calibrated against all-cause SMR
reported in UK Clinical Guideline CG101 [5]. Such sepa-
ration of SMRB attributed to background mortality and the
hospital case fatality rate in the model has enabled greater
flexibility regarding ranges of the hospital case fatality
rates, making the model applicable to a wider range of
settings.
Furthermore, adjustments to the RRR obtained from the
studies M2-124 and M2-125 were made to avoid double-
counting of the impact of lung function improvement on the
reduction of exacerbations. Because the results with roflu-
milast reported to date are based on 12-month studies, a
conservative approach was adopted considering that the lung
function benefits would last for 1 year only. However, evi-
dence from longer treatment trials in COPD (3- or 4-year
duration) suggests that the benefit of effective treatments
persists for years (TORCH [31, 32] and UPLIFT [33, 34]).
The following key assumptions regarding the efficacy of
roflumilast were made in the model. The model employs a
single pooled ratio of reduction of exacerbation rates
(RRR) that has been shown to be statistically significant in
two pivotal trials [15] that had identical designs. The single
RRR is applied to both the severe and very severe COPD
states, as the statistical analysis of trial data demonstrated
that the reduction of exacerbation rates was independent of
COPD severity. It was also assumed in the model that the
relative rate of reduction of exacerbations remains constant
over time. Data from the roflumilast clinical programme
did not provide any signals to suggest that patients would
develop a tolerance or resistance to roflumilast. An analysis
of time to first and subsequent exacerbations has confirmed
the sustained effect of roflumilast on exacerbations [35].
Assumptions of shorter durations of reduction of the
exacerbation effect in a sensitivity analysis demonstrated a
stable incremental cost-effectiveness ratio.
Reduction of hospital exacerbation rates
The pivotal roflumilast clinical trials [6] were designed to
estimate the statistically significant reduction rates of com-
munity-treated exacerbations and hospital-treated exacer-
bations combined. However, these studies were not powered
to produce a statistically significant reduction ratio of hos-
pital-treated exacerbations. The survival benefits of roflu-
milast treatment in the model are partly attributed to hospital
CFR and based on the assumption that exacerbation rates
result in certain proportions of hospital-treated exacerba-
tions as observed in the pivotal studies (0.155 and 0.244 in
severe and very severe COPD respectively [19]). These
assumptions could be further validated by including the
review of available data on hospitalisations for COPD.
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Comparator regimens and relation to the UK clinical
practice
The studies M2-124 and M2-125 used to populate the eco-
nomic model provided a combination of evidence on the
treatment effect of roflumilast on the reduction of exacer-
bations and improvement of lung function in patients with
severe and very severe COPD treated with concomitant
LABA. No direct evidence is available on the comparative
effectiveness of roflumilast versus other COPD regimens
representing a wide range of treatments available in the UK.
An attempt was made to synthesise various studies in a
network meta-analysis study in 2011 [36] that reported
estimates of the relative reduction of exacerbation rates in
patients treated with roflumilast versus a range of other
regimens. With a wide range of comparators, the relative
reduction of exacerbations had a similar magnitude to the
RRR drawn from the studies M2-124 and M2-125. However,
due to the nature of MTC, data in the study [36] were highly
uncertain, and no effect on lung function improvement was
reported.
A health economics study [37] based on the RRRs from
the MTC [36] showed that in the UK setting, roflumilast as
an add-on therapy to LAMA ? LABA/ICS has a broadly
similar exacerbation reduction ratio of 0.84 (95 % CI
0.74–0.95) and a comparable incremental cost-effective-
ness of £16,566 per QALY gained.
The cost-effectiveness model in this study attempts to
synthesise the best practices in COPD pharmacoeconomic
modelling and uses FEV1-based definitions of COPD
severity stages; the model is based on direct evidence
derived from a pooled analysis of two pivotal RCTs. The
analysis presented in this study suggests that adding rof-
lumilast to concomitant bronchodilator therapy (LABA)
can be an effective treatment option with an incremental
cost-effectiveness ratio that is within a widely accepted
range, i.e. £20,000-£30,000 per QALY gained.
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